OncoMatch/Clinical Trials/NCT03484299
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
Is NCT03484299 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Gemcitabine and FOLFIRINOX for pancreas cancer.
Treatment: Gemcitabine · FOLFIRINOX — Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage III
Lab requirements
Kidney function
gfr > ml/min/1.73m2
Liver function
ast/alt >3 times upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Louisville · Louisville, Kentucky
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03484299 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages